#### PREVENTION OF HEALTHCARE-ASSOCIATED INFECTIONS: KEY CHALLENGES AND FUTURE DIRECTIONS


David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics & Epidemiology Associate Hospital Epidemiologist, UNC Hospitals University of North Carolina at Chapel Hill, USA

Thanks to the following for some slides: Lauren DiBiase, Emily Sickbert-Bennett

## **LECTURE TOPICS**

- Tribute to Dr. William Rutala
- Importance of the changing healthcare environment
  - Aging population, growth of nursing homes, introduction of MDROs from community into the hospital
- Meeting CMS and Societal Expectations
  - Expectation of a "0" HAI infection rate, lack of risk adjustment, lack of validation of surveillance data
- Device-associated infections: A tale of poor engineering
  - Phacoemulsifier, heater-cooler units, duodenoscopes
- The threat of antibiotic/germicide resistant pathogens
  - *C. difficile*, norovirus, *Candida auris*
- The growing importance of non-device associated infections

#### HE STANDS FOR TRUTH, RESEARCH AND THE SCIENTIFIC WAY!



#### 32+ YEARS OF COLLABORATION! Rutala WA, Weber DJ – PubMed Citations (206 & counting)

| Number 1, 1985, JAMA  | Number 100, 2007, ICHE   |
|---|--|
| Obesity as a Predictor of Poor Antibody   | Compliance With Isolation Precautions at a University Hospital   |
| Response to Hepatitis B Plasma Vaccine  | David J. Weber, MD, MPH;<br>Emily E. Sickbert-Bennett, MS;   |
| David J. Weber, MD, MPH; William A. Rutala, PhD, MPH; Gregory P. Samsa, MS;<br>Jane E. Santimaw, RN; Stanley M. Lemon, MD   | Vickie M. Brown, RN, MPH; Rebecca H. Brooks, RN;<br>Irene P. Kittrell, RN; Brenda J. Featherstone, RN;<br>Tina L. Adams, RN; William A. Rutala, PhD, MPH                                     |
| Disinfectants used for environmental disinfection and new room<br>decontamination technology<br>William A. Rutala PhD, MPH <sup>a,b,</sup> *, David J. Weber MD, MPH <sup>a,b</sup> | A Prolonged Outbreak of KPC-3-<br>Producing Enterobacter cloacae and<br>Klebsiella pneumoniae Driven by Multiple<br>Mechanisms of Resistance Transmission<br>at a Large Academic Burn Center |
| Number 150, 2013, AJIC  | Number 200, 2017, AAC  |

#### WILLIAM A. RUTALA, PhD, MPH


#### Award and Honors

- Only person to have named awards by both APIC and SHEA
- Editorial Board, ICHE
- Advisor to CDC, FDA, EPA, FTC, US Congress
- Carole M DeMille Lifetime Achievement Award, APIC, 1999
- Barr Distinguished Alumni Award, UNC SPH, 2012
- SHEA Lectureship, 2012
- Kelsey Lecture, UK, 2001 and 2012
- Favero Lectureship, APIC, 2009


#### Accomplishments

- ~40 years in infection prevention
- >600 publications
- World's leading authority on sterilization and disinfection (author of CDC Guideline on S/D)
- Developed SPICE Program which has trained the IPs at >90% of all NC hospitals
- >370 invited presentations at state, national and international symposia

## FAMILY IS IMPORTANT TO A SUCCESSFUL CAREER




## **BILL'S SIGNIFICANT OTHER**






#### INTRODUCTION OF HAND HYGIENE TO REDUCE HAIS BY IGNAZ SEMMELWEIS



# <section-header><section-header><section-header><complex-block><image><image><image><image><image><image><image><image><image><image>



#### CLEARLY BILL HAS WEATHERED HOSPITAL EPIDEMIOLOGY BETTER THAN SEMMELWEIS





Unlike Semmelweis, Bill will spend his future enjoying his family, traveling (goal=100 countries), continuing to direct SPICE, and conducting infection prevention research

#### WELCOME UNC HOSPITALS' NEW HOSPITAL EPIDEMIOLOGIST, EMILY SICKBERT-BENNETT, PhD, MS


#### Awards and accomplishments


- 14 years experience in infection prevention
- Adjunct Asst. Professor, Epidemiology
- Research Asst. Professor, Medicine
- Bernard Greenberg Award for Excellence in Doctoral Research, Gillings SPH 2011
- Associate Editor, American Journal of Infection Control
- >45 peer-reviewed publications




## IMPORTANCE OF THE CHANGING HEALTHCARE ENVIRONMENT


Aging Population Growth of extended care facilities Increased introduction of MDROs from the community into the hospital







#### AGE-RELATED CHANGES IN 100-km ULTRA-MARATHON RUNNING PERFORMANCE



## **IMPACT OF HAIS IN LONG-TERM CARE**

- ~3.2 million Americans live in extended care facilities, 2008<sup>1</sup>
- ~1.0 million Americans reside in assisted living facilities, 2008<sup>1</sup>
- 1.6-3.8 million infections per year<sup>2</sup>
- Incidence of endemic infections = 1.8-13.5 infections per 1,000 resident days<sup>2</sup>
- Estimated several thousand outbreak occur per year<sup>2</sup>
- Infections are the leading reason for hospital transfer<sup>2</sup>

## **IMPACT OF HAIS IN NURSING HOMES**

#### **Nursing Homes**

- Number of nursing homes: 15,600 (2014)
- Proportion of nursing homes with for-profit ownership: 69.8% (2014)
- Number of licensed beds: 1.7 million (2014)
- Number of residents: 1.4 million (2014)

Nursing facilities, alternative residential care places, home care

• 2000=15 million; 2050=27 million

#### Impact

- 1.6-3.8 million infections per year
- Incidence of endemic infections = 1.8-13.5 infections per 1,000 resident days
- Estimated several thousand outbreak occur per year
- Infections are the leading reason for hospital transfer

CDC

#### OUTBREAKS OF HEPATITIS B DUE TO GLUCOSE MONITORING, UNS, 2009-10

Table 1. Analysis of Data from Epidemiologic Studies Conducted among Residents of Assisted Living Facilities during HBV Infection Outbreak Investigations Found to Be Associated with AMBG—United States, 2009–2010

|                                   | Total number |        | Residents included in   | n epidemiologic | study <sup>b</sup>      |                     |
|-----------------------------------|--------------|--------|-------------------------|-----------------|-------------------------|---------------------|
| State<br>(reference) <sup>a</sup> | of residents | R      | leceiving AMBG          | Not             | receiving AMBG          | RR (95% CI)         |
| · · ·                             | tested       | Tested | Acute HBV infection (%) | Tested          | Acute HBV infection (%) |                     |
| NC<br>(14)                        | 61           | 15     | 8 (53%); 6 died         | 25              | 0 (0%)                  | 27.6<br>(1.7–446.7) |
| VA<br>(15)                        | 44           | 5      | 3 (60%)                 | 26              | 1 (4%)                  | 15.6<br>(2.0–121.3) |
| VA<br>(16)                        | 126          | 13     | 12 (92%)                | 75              | 2 (3%)                  | 34.6<br>(8.7–137)   |
| FL<br>(17)                        | 48           | 10     | 6 (60%)                 | 38              | 1 (3%)                  | 22.8<br>(3.0–168.3) |

<sup>a</sup> NC = North Carolina; VA = Virginia; FL = Florida
<sup>b</sup> Includes only residents with acute HBV infection and those susceptible to HBV

Thompson ND, et al. J Diabetes Sci Technol 2011;5:1396-1402

#### INFECTION CONTROL PRACTICES IN ASSISTED LIVING FACILITIES

TABLE 3. Survey Data on Infection Control Practices and Compliance with Bloodborne Pathogens (BBP) Standard in 50 Assisted Living Facilities (ALFs) in Virginia, 2006

|  |          | ALFs, by size                   |         |                    |         | by type of<br>nership     |                      |
|--|----------|---------------------------------|---------|--------------------|---------|---------------------------|----------------------|
| Characteristic                             |          | 17-50  beds<br>( <i>n</i> = 15) |         | P, size            |         | Not individual $(n = 34)$ | P, type of ownership |
| Shared glucose monitoring devices          | 1 (10)   | 2 (13)                          | 7 (28)  | .46ª               | 2 (13)  | 8 (24)                    | .47ª                 |
| Did not use safety devices <sup>b</sup>    | 10 (100) | 15 (100)                        | 16 (64) | .01ª               | 14 (88) | 27 (79)                   | .70ª                 |
| Did not comply with OSHA BBP               |          |                                 |         |                    |         |                           |                      |
| standard <sup>c</sup>                      | 10 (100) | 11 (73)                         | 6 (24)  | <.001 <sup>a</sup> | 13 (81) | 14 (41)                   | .01 <sup>d</sup>     |
| Did not require infection control training | 5 (50)   | 5 (33)                          | 2 (8)   | .01ª               | 6 (38)  | 6 (18)                    | .16ª                 |

•16% shared glucose monitoring devices (without cleaning) between residents •34% did not offer employees HBV vaccine

Patel AS, et al. ICHE 2009;30:209-214

#### CHALLENGES IN INFECTION PREVENTION

#### • Patients

Patients frequently have risk factors for infection/colonization

- Older age, incontinence, poor functional status, malnutrition
- Chronic diseases: Diabetes, renal dysfunction, neurologic impairment
- Use of medical devices: Foley catheters
- Non-intact skin: Decubiti, diabetic foot ulcers
- Frequent hospital contact (e.g., dialysis)
- Medications (drugs that affect level of consciousness, immune function, gastric acid secretions, and normal flora)
- Patients frequently colonized/infected with MDROs
- Patients frequently receive antibiotics

#### CHALLENGES IN INFECTION PREVENTION

#### Infection control

- Patients often housed in multi-bed rooms
- Patients, even if colonized/infected, have contact with each other (e.g., common areas, dining area)
- Limited or no access to hallway sinks or alcohol-based hand rubs
- Facility may not have trained infection preventionist
- Facility unlikely to have an MD infection preventionist
- Likely low compliance with hand hygiene and environmental disinfection
- Limited studies in long-term care facilities on which to base recommendations

#### CHALLENGES IN INFECTION PREVENTION

- Environmental services (EVS)
  - Potentially less trained staff
  - Lack of infection control leadership (i.e., trained IP and hospital epidemiologist)
  - Terminal disinfection occurs infrequently (i.e., most patients long-term)
  - Many rooms will be multi-bed limiting use of "no touch" methods
  - Product cost likely to be more of an issue than for acute care hospitals

# DIVERSE SOURCES OF *C. difficile* INFECTION IDENTIFIED ON WHOLE GENOME SEQUENCING

| Table 1. Classification of 957 Cases of C. difficile           Relationship.☆                  | incention recording to | ine entre intestional osce          | to Denne a Generic | Site: Oxfordshire, UK                            |
|--|------------------------|-------------------------------------|--------------------|--|
| Classification   | Main Analysis          | Sensitivit                          | y Analysis         | 2007-2011  |
|  | 0–2 SNVs               | 0 SNVs<br>number of cases (percent) | 0–10 SNVs          | 1250 <i>C. difficile</i> cases<br>98% sequenced  |
| Genetically distinct   | 624 (65)               | 717 (75)                            | 428 (45)           | Only 33% linked                                  |
| Genetically linked to any previous case  | 333 (35)               | 240 (25)                            | 529 (55)           |  |
| Closest genetic link through hospital contact<br>Any hospital contact within plausible limits† | 181 (19)               | 144 (15)                            | 224 (23)           | Of 333 patients with                             |
| Ward contact †   | 126 (13)               | 98 (10)                             | 136 (14)           | linked cases; 38% had                            |
| Ward contamination only:   | 5 (1)                  | 7 (1)                               | 8 (1)              | close hospital contact                           |
| Shared medical specialty only†   | 17 (2)                 | 15 (2)                              | 28 (3)             | with another patient and                         |
| Other hospital-wide contact only†  | 12 (1)                 | 9 (1)                               | 22 (2)             |  |
| Ward contamination and hospital-<br>wide contact   | 21 (2)                 | 15 (2)                              | 30 (3)             | 36% had no hospital or<br>community contact with |
| Closest genetic link through community<br>contact, with no hospital contact                    |                        |                                     |                    | another patient                                  |
| Any community contact  | 32 (3)                 | 23 (2)                              | 63 (7)             |  |
| Same general medical practice  | 15 (2)                 | 10 (1)                              | 37 (4)             | Eyre D, et al.                                   |
| Same residential postal-code district, but<br>different general medical practice               | 17 (2)                 | 13 (1)                              | 26 (3)             | NEJM 2013;369:1195                               |
| Genetically related but no known hospital or<br>community contact                              | 120 (13)               | 73 (8)                              | 242 (25)           |  |

### MEETING CMS AND SOCIETAL EXPECTATIONS

Expectation of "0" infection rate Lack of risk adjustment Lack of validation of individual hospitals reporting

#### VALUE BASED PURCHASING: BENCHMARKS AND THRESHOLDS

| FY2019 VBP | HAI Benchmarks & | & Thresholds |
|------------|------------------|--------------|
| Measure    | Benchmark        | Threshold    |
| CLABSI     | 0.000            | 0.860        |
| CAUTI      | 0.000            | 0.822        |
| COLO SSI   | 0.000            | 0.783        |
| HYST SSI   | 0.000            | 0.762        |
| LabID MRSA | 0.000            | 0.854        |
| LabID CDI  | 0.113            | 0.924        |

Gase K. Presented at SHEA, St. Louis, 2017


#### LEADING CAUSES OF DEATH, US, 2014


|                         | Deaths  | Rate | Age-Adjusted Rate 2014, 2010, 2005 | % Total Deaths |
|-------------------------|---------|------|------------------------------------|----------------|
| Accidents               | 136,053 | 42.7 | 40.5, 38.0 (+6.1%), 39.5 (+2.5%)   | 5.2%           |
| MVA                     | 35,092  | 10.8 | 13.1, 10.6 (+19/1%), 8.0 (+38.9%)  |                |
| Diabetes                | 76,488  | 24.0 | 20.9, 20.8 (+0.5%), 24.9 (-16.0%)  | 2.9%           |
| Influenza and pneumonia | 55,227  | 17.3 | 15.1, 15.1 (0%), 21.0 (-39.3%)     | 2.1%           |
| Suicide                 | 42,773  | 13.4 | 13.0, 12.1 (+6.9%), 10.9 (+16.1%)  | 1.6%           |

HAIs = ~75,000 deaths (rank = #8)

http://www.medicalnewstoday.com/articles/282929.php; Health, US, 2015, CDC

## HAI INCIDENCE OVER TIME, UNC





#### DENSITY OF BACTERIA ON THE HUMAN BODY

| Table 1. Bounds for bacteria number in different of |   | ns and volume.                         |   |
|---|---|--|---|
| Location  | Typical concentration of bacteria <sup>(1)</sup><br>(number/mL content) | Volume (mL)                            | Order of magnitude bound<br>for bacteria number |
| Colon (large intestine)                             | 1011  | 400 (2)                                | 1014  |
| Dental plaque                                       | 1011  | <10                                    | 10 <sup>12</sup>                                |
| lleum (lower small intestine)                       | 10 <sup>8</sup>   | 400 (5)                                | 1011  |
| Saliva  | 10 <sup>9</sup>   | <100                                   | 1011  |
| Skin  | <10 <sup>11</sup> per m <sup>2</sup> (3)                                | 1.8 m <sup>2 (4)</sup>                 | 1011  |
| Stomach   | 10 <sup>3</sup> -10 <sup>4</sup>  | 250 <sup>(5)</sup> -900 <sup>(6)</sup> | 10 <sup>7</sup>                                 |
| Duodenum and Jejunum (upper small intestine)        | 10 <sup>3</sup> -10 <sup>4</sup>  | 400 (5)                                | 10 <sup>7</sup>                                 |

Sender R, et al. PLoS Biol 2016;14:e1002533

# CONCLUSIONS

- Decrease in HAIs greater than decrease in many other important causes of death
- Reaching "0" HAIs is not possible given the following: large numbers of microbes on body surfaces, inability to sterilize human body surfaces, and need for indwelling devices to provide medical care
- Cost of HAI prevention, per case prevented, will rise as we decrease HAI incidence

#### PATIENT LEVEL RISK FACTORS FOR HAIS – ADJUSTMENT BY NHSN

| CLA-BSI                                     | CA-UTI             | SSI                       | C. difficile               |
|---|--------------------|---------------------------|----------------------------|
| Device                                      | Device             | Glucose control           | Age                        |
| ICU location                                | Gender             | Type of hair removal      | Antibiotics                |
| Prolonged hospitalization prior to catheter | Drainage<br>system | Antibiotic prophylaxis    | Broad spectrum antibiotics |
| IJ catheter                                 | Age                | Temp control              | Community colonization     |
| Femoral catheter                            |                    | Supplemental O2           | Immunosuppression          |
| Neutropenia                                 |                    | ETOH-antiseptic skin prep |                            |
| Prematurity                                 |                    | Wound protectors (GI)     |                            |
| Parenteral nutrition                        |                    | Diabetes*                 |                            |
| Blood transfusion (kids)                    |                    | ASA score*                |                            |
| Reduce RN to Pt ratio, ICU                  |                    | Gender*                   |                            |
|   |                    | BMI*                      | * Included in for some ops |
|   |                    | Duration*                 | Risk factors based on SHEA |
|   |                    | Scope *                   | Guidelines                 |

## Risk factors for COLO and HYST


| NHSN operative         | Risk factors included in  |
|------------------------|---|
| procedures             | SIR logistic regression model   |
| Colon surgery (COLO)   | Age, anesthesia, ASA, duration,<br>endoscope, medical school affiliation,<br>location bed size, wound class |
| Abdominal hysterectomy | Age, anesthesia, ASA, duration,   |
| (HYST)                 | endoscope, location bed size  |

http://www.cdc.gov/nhsn/PDFs/pscManual/SSI ModelPaper.pdf

#### Limitations of NHSN SSI Risk Adjustment

- Model generated from predictor variables of convenience that exist in NHSN database rather than all known risk factors
  - Patient level variables = Age, gender, wound class, ASA score, and 2-3 other variables
- Predictor variables chosen for inclusion in the model on the basis of statistical parameters alone
  - Unknown relevance of bed size and medical school affiliation
- Study sample over emphasized large hospitals
- Overall change in c-index is modest
  - Only 16 (41%) of procedure-specific models have c-index >0.7

Moehring RW, Anderson DJ. ICHE 2011;32:987



## "Don't look, don't find..."

nhsn@cdc.gov Siddhert-Bennett, Emily

#### NORTH CAROLINA

Hospitals that report zero MRSA infections

Catawba Valley Medical Center, Hickory

Adherence to the Centers for Disease Control and Preve ssage INHSN Communique\_with signatures.pdf (299 KB) 🔛 Mes

#### X NHSN

Frye Regional Medical Center, Hickory Halifax Regional Medical Center, Roanoke Rapids

- Iredell Memorial Hospital, Statesville
- Margaret R. Pardee Memorial Hospital, Hendersonville
- Morehead Memorial Hospital, Eden
- Novant Health Brunswick Medical Center, Bolivia
- Randolph Hospital, Asheboro
- Hospitals that report zero C. diff infections
- Hugh Chatham Memorial Hospital, Elkin
- J. Arthur Dosher Memorial Hospital, Southport
- Kings Mountain Hospital, Kings Mountain
- Person Memorial Hospital, Roxboro
- Sandhills Regional Medical Center, Hamlet
- Transylvania Regional Hospital, Brevard

To: NHSN Users:

CDC's National Healthcare Safety Network (NHSN) is the nation's most comprehensive medical event tracking system that is currently utilized by more than 16,000 US. Healthcare facilities. NHSN provides critical data to guide prevention efforts aimed at protecting patients.

Sent: Wed 10/7/2015 1:39 |

-

ention's (CDC's) Infection Defi

In response to anecdotal reports of intentional non-reporting of infection data, CDC and CMS are jointly issuing a reminder that addresses concerns about healthcare facility non-reporting of healthcare-associated infections events. That document is attached to this email. While there is no evidence of a widespread issue, CDC and CMS want to emphasize that accurate reporting to NHSN through strict adherence to the NHSN definitions is critical.

CDC and CMS are committed to ensuring data accuracy and reliability for guiding prevention priorities and protecting patients. Identifying infections and making sure that patients receive the highest quality of care is our top priority.

Thank you,

The NHSN Team

#### **DEVICE-ASSOCIATED INFECTIONS:** A TALE OF POOR ENGINEERING

Phacoemulsifier Heater-Cooler Units Duodenoscopes

#### P. aeruginosa-RELATED POSTOPERATIVE ENDOPHTHALMITIS LINKED TO A CONTAMINATED PHACOEMULSIFIER


|                                   |       |                       |        |        | Patient No | -t     |       |           |                            |
|-----------------------------------|-------|-----------------------|--------|--------|------------|--------|-------|-----------|----------------------------|
| Clinical Characteristic           | 1     | 2                     | 3      | 4      | 5          | 6      | 7     | 8         | 9                          |
| Demographic features              |       |                       |        |        |            |        |       |           |                            |
| Age, y                            | 74    | 70                    | 83     | 84     | 64         | 61     | 66    | 48        | 85                         |
| Sex                               | Male  | Female                | Female | Female | Female     | Male   | Male  | Male      | Male                       |
| AODM                              | Yes   | Yes                   | No     | No     | No         | No     | No    | No        | No                         |
| Operative features                |       |                       |        |        |            |        |       |           |                            |
| Eye involved                      | Right | Left                  | Right  | Left   | Right      | Right  | Left  | Right     | Left                       |
| Lens implanted                    | Yes   | No                    | Yes    | Yes    | Yes        | Yes    | Yes   | Yes       | No                         |
| Cataract extraction method        | Phaco | Corneal<br>relaxation | Phaco  | Phaco  | Phaco      | Phaco  | Phaco | Phaco     | Corneal<br>transplantation |
| Phacoemulsification time, s       | 57    | NA                    | 42     | 44     | 25         | 37     | 39    | 22        | NA                         |
| Endophthalmitis onset<br>Cultures | POD 1 | NA                    | POD 1  | NA     | POD 1 (PM) | POD 3  | NA    | POD 2     | NA                         |
| Site                              | AC    | NA                    | AC     | NA     | PC         | PC     | NA    | PC        | NA                         |
| Results                           | NG    | NA                    | PAt    | NA     | PA         | PA     | NA    | PA and PM | NA                         |
| Intravitreal antibiotic therapy§  |       |                       |        |        |            |        |       |           |                            |
| Without vitrectomy                | 1     | NA                    | 1      | NA     | 0          | 1      | NA    | 0         | NA                         |
| With vitrectomy                   | 1     | NA                    | 1      | NA     | 2          | 1      | NA    | 2         | NA                         |
| Visual acuity                     |       |                       |        |        |            |        |       |           |                            |
| Preoperative                      | 20/50 | NA                    | 20/100 | NA     | 20/50-1    | 20/400 | NA    | 20/200    | NA                         |
| Postoperative                     |       |                       |        |        |            |        |       |           |                            |
| Worst                             | HM    | NA                    | HM     | NA     | HM         | HM     | NA    | HM        | NA                         |
| Best                              | 20/30 | NA                    | 20/20  | NA     | 20/20      | 20/20  | NA    | 20/20     | NA                         |

\*AODM indicates type 2 diabetes mellitus; Phaco, cataract extraction using phacoemulsification; POD, postoperative day; PM, Proteux mirabilis (2 colonies); AC, tatior chamber; PC, postoperative chamber (vitrae) tap); MG, no growth; PA, Pseudomonas aeruginosa; HM, hand movements; and NA, data not applicable. The operative order is the same an est the patient number. If a difficit, a-hemolytic streptococcus and *Enterococcus* spacies grew from the broth only. Spata are given as the number of times therapt was administered. [This patient experienced late development of relinal detachment.

Hoffmann KK, Weber DJ, Gergen MF, Rutala WA. AMA

#### P. aeruginosa-RELATED POSTOPERATIVE ENDOPHTHALMITIS LINKED TO A CONTAMINATED PHACOEMULSIFIER

- Background: Cataract extraction is common medical procedure
- Outbreak: SPICE notified in 1999 about a cluster of postoperative endophthalmitis (AR = 5 of 7; all right eye)
- Evaluation:
  - Cultures of all medications negative
  - Scrub sink = *P. aeruginosa* (not outbreak strain)
  - Phacoemulsifier internal channel = P. aeruginosa (outbreak strain by PFGE)
- Conclusion
  - Poorly designed device which allowed contamination of internal channels




#### *M. CHIMAERA* OUTBREAK ASSOCIATED WITH CONTAMINATED HEATER-COOLER UNITS

- July 2015: Invasive *M. chimaera* reported in 6 patients who underwent cardiac surgery with implants, 2008-2012, at one hospital in Zurich, Switzerland
- Investigations revealed *M. chimaera* in the water tanks of heater-cooler units (HCU); air sampling also positive for *M. chimaera* when the units were running
- Additional cases confirmed in several European countries and in US
- Studies suggest NTM from the HCU aerosolized from contaminated water in the device into the air
- Risk of disease not entirely clear
  - 0.39 cases per 10,000 person-years (5 year risk){Chand M, et al. CID 2017;64:335-42}
  - If hospital has had 1 case, patient risk between 0.1% and 1% {CDC}
  - Risk higher if prosthetic material implanted
  - Mortality >50%
- Impact of outbreak: >250,000 cardiac bypass procedures done each year in US using HCU (CDC 2016).

# Global outbreak of HCU-associated *M. chimaera*









#### RECENT DUODENSOCPE-RELATED OUTBREAKS OF MRDO WITHOUT REPROCESSING BREACHES

| MDRO                   | Resistance                    | No. Pts<br>(infected) | Propagated<br>Outbreak | Positive<br>Scope(s) | Molecular Link  | Reference          |
|------------------------|-------------------------------|-----------------------|------------------------|----------------------|-----------------|--------------------|
| K. pneumonaie          | CRE (bla <sub>oxa-232</sub> ) | 15 (8)                | No                     | No                   | PCR*            | Kim S, 2016        |
| <i>E. coli</i> (Amp C) | CRE (bla <sub>cmy-2</sub> )   | 35                    | No                     | Yes (2)              | PCR*, PFGE      | Wendorf KA, 2015   |
| K. pneumoniae          | CRE (bla <sub>oxa-48</sub> )  | 12                    | Yes                    | No                   | PCR*, PFGE      | Kola A, 2015       |
| K. pneumoniae          | $CRE\;(bla_{KPC})$            | ?                     | No                     | Yes (3)              | PCR*, PFGE, WGS | Marsh J, 2015      |
| E. coli                | CRE (NDM)                     | 39                    | Yes                    | Yes                  | PFGE            | Epstein L, 2015    |
| P. aeruginosa          | VIM-2                         | 22                    | Yes                    | Yes                  | Yes             | Verfaillie C, 2015 |
| E. coli                | NDM-1                         | 3 (3)                 | No                     | No                   | Not done        | Smith Z, 2015.     |
| K. pneumoniae          | $CRE\;(bla_{kpc-2,SHV})$      | 13                    | Yes                    | Yes                  | PCR*, PFGE      | Carbonne A, 2010   |

PCR\*, PCR for resistance gene; CRE, carbapenem-resistant enterobacteriaceae; WGS, whole genome sequencing

#### Endemic Transmission of Infections Associated with GI Endoscopes May Go Unrecognized



- Inadequate surveillance of outpatient procedures for healthcare-associated infections
- Long lag time between colonization and infection
- Low frequency of infection
- Pathogens "usual" enteric flora
- Risk of some procedures might be lower than others (colonoscopy versus ERCP where normally sterile areas are contaminated in the latter)

## PREVENTING INFECTIONS ASSOCIATED WITH ENDOSCOPY (especially ERCP)

| ELSEVIER          | American Journal of Infection Control  | American Journal of<br>Infection Control                 |
|-------------------|--|--|
| Major article     |  |  |
|                   | carbapenem-resistant <i>Enterobacteriaceae</i> infections ith duodenoscopes: What can we do to prevent | CroseMark  |
| William A. Rutala | a PhD, MPH མམঙ་, David J. Weber MD, MPH མ୬   |  |
| 13                | NFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JUNE 2015, VOL. 36, NO. 6                                     |  |
|                   | COMMENTARY   |  |
|                   | William A. Rutala, PhD, MPH; <sup>1,2</sup> David J. Weber, MD, MPH <sup>1,2</sup>                     |  |
|                   |  |  |
| _                 |  |  |
| EDITORIAL         | Editorials represent the opini   | ons of the authors and JAMA nerican Medical Association. |
| EDITORIAL         | Editorials represent the opini   |  |
|                   | Editorials represent the opini<br>and not those of the Au  |  |
| Gastroint         | Editorials represent the opini<br>and not those of the Ar<br>estinal Endoscopes                        |  |
| Gastroint         | Editorials represent the opini<br>and not those of the Au  |  |

#### Current Enhanced Methods for Reprocessing Duodenoscopes

# Hospitals performing ERCPs should do one of the following (priority ranked); doing nothing is not an option:

- 1. Ethylene oxide sterilization after high level disinfection with periodic microbiologic surveillance
- 2. Double high-level disinfection with periodic microbiologic surveillance
- 3. High-level disinfection with scope quarantine until negative culture
- 4. Liquid chemical sterilant processing system using peracetic acid (rinsed with extensively treated potable water) with periodic microbiologic surveillance
- 5. High-level disinfection with periodic microbiologic surveillance

#### Potential Future Methods to Prevent GI-Endoscope Related Outbreaks

- Steam sterilization for GI endoscopes
- Disposable sterile GI endoscopes (disposable bronchoscopes available)
- Improved GI endoscope design (to reduce or eliminate challenges noted earlier)
- Use of non-endoscope methods to diagnosis or treat disease (e.g., capsule endoscopy, blood tests to detect GI cancer, stool DNA test)
- New low temperature sterilization methods proving SAL 10<sup>-12</sup> achieved (or optimizing current LTST)

Rutala WA, Weber WA. Infect Control Hosp Epidemiol 2015, In press

#### DEVICE-ASSOCIATED OUTBREAKS: SOLUTIONS


- FDA responsibilities
  - Ensure that all medical devices are safe and effective
  - Ensure that all manufacturer's of a re-usable medical device provide a validated method for cleaning and disinfection/sterilization
  - Require that all re-usable semicritical devices (e.g., duodenoscopes, arthroscopes) that enter sterile tissue/body spaces can be sterilized
- Manfacturer's responsibilities
  - Develop new devices that eliminate hazards associated with heater-cooler units and duodenoscopes
  - Demonstrate safety and efficacy (i.e., reduction in HAIs) in RCTs

#### THE THREAT OF ANTIBIOTIC/GERMICIDE RESISTANT PATHOGENS


#### MULTIDRUG-RESISTANT PATHOGENS

- Germicide resistant
  - C. difficile
  - HPV
  - Norovirus
  - *Candida aureus*


- Antibiotic resistant
  - MRSA
  - VRE
  - MDR-Acinetobacter
  - MDR-P. aeruginosa
  - Extended-spectrum betalactamase producers (ESBLs)
  - Carbapenem-resistant *Enterobacteriaceae* (CRE)



#### UNC RATES OF MULTIDRUG RESISTANT PATHOGENS, 2003-2016



#### TRANSMISSION MECHANISMS INVOLVING THE SURFACE ENVIRONMENT



#### EFFICACY OF ALCOHOL AS A HAND HYGIENE AGENT AGAINST *C. difficile*

 TABLE 1.
 Mean Clostridium difficile Colony Counts after Different

 Hand Hygiene Interventions According to the Whole-Hand Protocol

| Intervention                      | Mean count (95% CI),<br>log <sub>10</sub> CFU/mL |
|-----------------------------------|--|
| Warm water and plain soap         | 1.99 (1.80-2.09)                                 |
| Cold water and plain soap         | 1.90 (1.58-2.22)                                 |
| Warm water and antibacterial soap | 2.31 (2.04-2.58)                                 |
| Antiseptic hand wipe              | 3.25 (3.04-3.45)                                 |
| Alcohol-based handrub             | 3.74 (3.40-4.07)                                 |
| No intervention                   | 3.82 (3.54-4.10)                                 |

 Probability of heavy contamination (TNTC) following different HH interventions: warm water and plain soap = 0, cold water and plain soap = 0, warm water and antibacterial soap = 0, antiseptic hand wipe = 0.05, alcohol-based handrub = 0.43, and no hand hygiene = 1

Oughton MT, et al. ICHE 2009;30:939-944


#### SURFACE DISINFECTION: EFFECTIVENESS OF DIFFERENT METHODS vs *C. difficile*

|                                      | Wipe and/or spray method |                       |                                  |                            |                                |                   |
|--------------------------------------|--------------------------|-----------------------|----------------------------------|----------------------------|--------------------------------|-------------------|
| Product                              | Saturated cloth*         | Spray (10 s) and wipe | Spray, wipe, spray (1 min), wipe | Disposable<br>pop-up wipes | Spray, wipe,<br>spray, air dry | Spray and air dry |
| Ecolab QC-53, detergent              |                          |                       |                                  |                            |                                |                   |
| Reduction                            | 3.38 (1.61-5.16)         | 3.28 (2.18-4.38)      | 4.02 (3.68-4.35)                 | NT                         | 2.90 (1.34-4.45)               | <2.00 (1.78-2.21) |
| Drying time, min:s<br>Ecolab A456-II | 2:09                     | 4:18                  | 3:34                             | NT                         | 24:26                          | 28:11             |
| Reduction                            | 3.14 (2.01-4.27)         | 2.98 (1.92-4.04)      | 4.18 (3.46-4.90)                 | NT                         | 2.90 (1.52-4.27)               | <2.00 (1.78-2.21) |
| Drying time, min:s                   | 2:26                     | 6:18                  | 4:44                             | NT                         | 24:00                          | 30:14             |
| 1:10 Bleach                          |                          |                       |                                  |                            |                                |                   |
| Reduction                            | 3.90 (2.87-4.92)         | 4.48 (4.26-4.69)      | 4.48 (4.26-4.69)                 | NT                         | 4.48 (4.26-4.69)               | 3.44 (1.65-5.22)  |
| Drying time, min:s                   | 1:45                     | 5:18                  | 5:21                             | NT                         | 51:08                          | 39:40             |
| Kimtech One-Step Germicidal Wipe     |                          |                       |                                  |                            |                                |                   |
| Reduction                            | NT                       | NT                    | NT                               | 4.18 (4.18-4.18)           | NT                             | NT                |
| Drying time, min:s                   | NT                       | NT                    | NT                               | 4:06                       | NT                             | NT                |
| Clorox Germicidal Wipe               |                          |                       |                                  |                            |                                |                   |
| Reduction                            | NT                       | NT                    | NT                               | 3.98 (3.23-4.72)           |                                | NT                |
| Drying time, min:s                   | NT                       | NT                    | NT                               | 1:47                       | NT                             | NT                |
| Clorox #9255-41-1 and 3              |                          |                       |                                  |                            |                                |                   |
| Reduction                            | NT                       | 6.14 (6.14-6.14)      | NT                               | NT                         | NT                             | 5.96 (5.22-6.70)  |
| Drying time, min:s                   | NT                       | 2:49                  | NT                               | NT                         | NT                             | 40:14             |

Rutala WA, Gergen MF, Weber DJ. ICHE 2012;33:1255-58


#### ENDOSCOPE REPROCESSING: CHALLENGES Susceptibility of Human Papillomavirus


- Most common STD
- In one study, FDA-cleared HLD, no effect on HPV
- Finding inconsistent with other small, nonenveloped viruses such as polio and parvovirus
- Further investigation needed: test methods unclear; glycine; organic matter; comparison virus
- Conversation with CDC: validate and use HLD consistent with FDA-cleared instructions (no alterations)



J Meyers et al. J Antimicrob Chemother, Epub Feb 2014

#### EFFECTIVENESS OF DISINFECTANTS AGAINST CANDIDA AURIS







## SOLUTIONS

#### • MDR pathogens

- Anti-infective stewardship
- Develop new anti-infectives
- Develop non-antibiotic methods to treat infection
- Vaccine development (e.g., MRSA, *C. difficile*, TB, malaria)
- Germicide resistant or reduced susceptibility pathogens
  - Develop new germicides
  - Revise recommendations to use appropriate cidal agents
  - Develop new methods of killing pathogens (e.g., UV devices, hydrogen peroxide systems)

#### IMPORTANCE OF NON-DEVICE ASSOCIATED INFECTIONS





#### **RECOMMENDATIONS TO DECREASE RISK OF VAP, US**

| Recommendation                | CDC, 2003 | IDSA, 2005 | APIC, 2005 | SHEA, 2014 |
|-------------------------------|-----------|------------|------------|------------|
| Hand hygiene                  | Yes       | Yes        | Yes        |            |
| Microbiologic monitoring      | Yes       | Yes        | Yes        | Yes        |
| Device removal                |           |            | Yes        | Yes        |
| Avoid intubation              | Yes       | Yes        | Yes        |            |
| Reduction of antibiotics      |           |            | Yes        |            |
| Avoid reintubation            | Yes       | Yes        |            |            |
| Promote NIV if possible       | Yes       | Yes        | Yes        | Yes        |
| Orogastric tube               | Yes       | Yes        |            |            |
| Bed elevation                 | Yes       | Yes        | Yes        | Yes        |
| Subglottic aspiration         | No        | Yes        | Yes        | Yes        |
| Oral decontamination          | No        | No         | No         | No         |
| Selective gut decontamination | No        | No         | No         | No         |

No guideline has any recommendation to reduce HAP! Adapted from Passaro L, et al. Antimicrobial Resistance Infect Control 2016;5:43

## CONCLUSIONS

- Expand surveillance to track non-device associated HAIs
- Determine risk factors for non-device associated HAIs
- Develop interventions to reduce non-device associated HAIs

## **ADDITIONAL CHALLENGES**

- New complex devices (e.g., da Vinci surgery)
- Obtaining behavioral change
- Meeting expectations
- We have moved from seeking percent reductions in HAIs each year to competition to see who can decrease HAIs fastest
- Maintaining preparedness for highly-communicable disease (e.g., Ebola)
- Infection control in ambulatory care
- Maintaining proficiency in disinfection and sterilization
- Lack of new antimicrobials
- Integrating with institutions larger QI concerns
- Xenotransplantation?

### **NEW TOOLS**

- New diagnostics (MACDI-TOF)
- Rapid diagnostics (influenza, RSV, TB, etc.)
- New germicides (e.g., improved hydrogen peroxide)
- New room disinfection technologies (i.e., UV devices, H<sub>2</sub>O<sub>2</sub> systems)
- Tools for monitoring room cleaning (e.g., fluorescent dye)
- New tools of molecular epidemiology for assessing outbreaks (e.g., whole genome sequencing)
- Non-observed based methods for assessing hand hygiene compliance

#### HE STANDS FOR TRUTH, RESEARCH AND THE SCIENTIFIC WAY!

